DUBLIN--(BUSINESS WIRE)--The "Traumatic Brain Injury - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Traumatic Brain Injury - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 8, 77 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Traumatic Brain Injury - Overview
- Traumatic Brain Injury - Therapeutics Development
- Traumatic Brain Injury - Therapeutics Assessment
- Traumatic Brain Injury - Companies Involved in Therapeutics Development
- Traumatic Brain Injury - Drug Profiles
- Traumatic Brain Injury - Dormant Projects
- Traumatic Brain Injury - Discontinued Products
- Traumatic Brain Injury - Product Development Milestones
- Appendix
Companies Mentioned
- Alexion Pharmaceuticals Inc
- ALSP Inc
- AlzeCure Pharma AB
- AMAG Pharmaceuticals Inc
- Amarantus Bioscience Holdings Inc
- Anagin Inc
- Aptinyx Inc
- Athersys Inc
- Avanir Pharmaceuticals Inc
- Biogen Inc
- CalciMedica Inc
- Cantex Pharmaceuticals Inc
- CereSpir Inc
- Cognosci Inc
- Complement Pharma BV
- Eisai Co Ltd
- Epigen Biosciences Inc
- Hemarina SA
- Hoverink Biotechnologies Inc
- International Stem Cell Corp
- Ischemix Inc
- JT Pharmaceuticals Inc
- Levolta Pharmaceuticals Inc
- Mapreg SAS
- Neuralstem Inc
- Neuren Pharmaceuticals Ltd
- NeuroNascent Inc
- NeuroVive Pharmaceutical AB
- New World Laboratories Inc
- NoNO Inc
- NuvOx Pharma LLC
- Nyrada Inc
- Oxeia Biopharmaceuticals Inc
- Peptron Inc
- Prevacus Inc
- ProThera Biologics Inc
- QR Pharma Inc
- Qrons Inc
- Radikal Therapeutics Inc
- RegeneRx Biopharmaceuticals Inc
- Resolys Bio Inc
- Rubicon Biotechnology Inc
- Sage Therapeutics Inc
- Silver Creek Pharmaceuticals Inc
- STATegics Inc
- Stemedica Cell Technologies Inc
- SynZyme Technologies LLC
- Tetra Discovery Partners LLC
- Therapeutic Solutions International Inc
- Therapix Biosciences Ltd
- TikoMed AB
- Tiziana Life Sciences Plc
- vasopharm GmbH
- VG Life Sciences Inc
- Virogenomics BioDevelopment Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/allrfb
